Chemotherapy in the Management of Retinoblastoma

  • C. Rodriguez-GalindoEmail author
Part of the Pediatric Oncology book series (PEDIATRICO)


Treatment of retinoblastoma aims to save life and preserve useful vision, and thus needs to be individualized. Factors that need to be considered include unilaterality or bilaterality of the disease, potential for vision, and intraocular and extraocular staging. A multidisciplinary approach is pivotal, and it is in this context that the role of chemotherapy must be discussed.

The first clinical experience with chemotherapy in the treatment of retinoblastoma using nitrogen mustard was reported in 1953 (Kupfer 1953). Institutional experiences in the management of extraocular retinoblastoma were reported subsequently, usually applying regimens modeled after the treatment regimens for metastatic neuroblastoma (Lonsdale et al. 1968; Pratt et al. 1985). Since then, the role of chemotherapy has been expanding, and now it is a main component in the management of intraocular disease.

Retinoblastoma is a very chemosensitive disease; in general, chemotherapy is indicated in patients with extraocular disease, in the subgroup of patients with intraocular disease with high-risk histologic features, and in patients with bilateral disease in conjunction with aggressive focal therapies. Agents with documented efficacy include microtubule inhibitors (vincristine and paclitaxel), platinum compounds (cisplatin and carboplatin), topoisomerase II inhibitors (teniposide and etoposide), alkylating agents (cyclophosphamide and ifosfamide), anthracyclines (doxorubicin and idarubicin), and topoisomerase I inhibitors (topotecan) (Schouten-van Meeteren et al. 2002; Rodriguez-Galindo et al. 2007).


Retinal Pigment Epithelium Main Side Effect Main Drug Interaction Fibrin Sealant Cytochrome P450 Isoenzyme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abramson DH, Greenfield DS, Ellsworth RM (1992) Bilateral retinoblastoma: correlations between age at diagnosis and time course for new intraocular tumors. Ophthalmic Paediatr Genet 13:1-7CrossRefPubMedGoogle Scholar
  2. Abramson DH, Gamell LS, Ellsworth RM et al (1994) Unilateral retinoblastoma: new intraocular tumours after treatment. Br J Ophthalmol 78:698-701CrossRefPubMedGoogle Scholar
  3. Abramson DH, Frank C, Chantada G et al (1999a) Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. Ophthalmic Genet 20:31-36CrossRefPubMedGoogle Scholar
  4. Abramson D, Frank C, Dunkel I (1999b) A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 106:1947-1950CrossRefPubMedGoogle Scholar
  5. Abramson DH, Lawrence SD, Beaverson KL, Lee TC, Rollins IS, Dunkel IJ (2005) Systemic carboplatin for retinoblastoma: change in tumour size over time. Br J Ophthalmol 89:1616-1619CrossRefPubMedGoogle Scholar
  6. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP (2008) A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma: initial results. Ophthalmology 115:1398-1404CrossRefPubMedGoogle Scholar
  7. Antonelli CBG, Steinhorst F, Ribeiro KCB et al (2003) Extraocular retinoblastoma: a 13-year experience. Cancer 98:1292-1298CrossRefGoogle Scholar
  8. Antonelli CBG, Ribeiro KCB, Steinhorts F, Novaes PERS, Chojniak MM, Malogolowkin M (2006) Treatment of retinoblastoma patients with chemoreduction plus local therapy: experience of the AC Camargo Hospital, Brazil. J Pediatr Hematol Oncol 28:342-345CrossRefGoogle Scholar
  9. Athale UH, Stewart C, Kuttesch JF et al (2001) Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 20:88-95CrossRefGoogle Scholar
  10. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF (1996) Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 37:195-202CrossRefPubMedGoogle Scholar
  11. Blanco J, Dervieux T, Edick M et al (2001) Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 98:10338-10343CrossRefPubMedGoogle Scholar
  12. Blaney SM, Heideman R, Berg S et al (2003) Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21:143-147CrossRefPubMedGoogle Scholar
  13. Bu H-Z, Gukasyan HJ, Goulet L, Lou X-J, Xiang C, Koudriakova T (2007) Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 8:91-107CrossRefPubMedGoogle Scholar
  14. Carcaboso AM, Bramuglia GF, Chantada GL et al (2007) Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci 48:3761-3767CrossRefPubMedGoogle Scholar
  15. Chan HS, Canton MD, Gallie BL (1989) Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res 9:469-474PubMedGoogle Scholar
  16. Chan H, DeBoer G, Thiessen J et al (1996) Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 2:1499-1508PubMedGoogle Scholar
  17. Chan H, Lu Y, Grogan T et al (1997) multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 57:2325-2330PubMedGoogle Scholar
  18. Chantada G, Davila MTG, Fandiño A et al (1999a) Retinoblastoma with low risk for extraocular relapse. Ophthalmic Genet 20:133-140CrossRefPubMedGoogle Scholar
  19. Chantada G, Fandiño A, Mato G, Casak S (1999b) Phase II window of idarubicin in children with extraocular retinoblastoma. J Clin Oncol 17:1847-1850PubMedGoogle Scholar
  20. Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schvartzman E (2003) Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol 40:158-161CrossRefPubMedGoogle Scholar
  21. Chantada G, Fandiño A, Dávila MTG et al (2004a) Results of a prospective study for the treatment of retinoblastoma. Cancer 100:834-842CrossRefPubMedGoogle Scholar
  22. Chantada G, Fandino A, Casak S et al (2004b) Activity of topotecan in retinoblastoma. Ophthalmic Genet 25:37-43CrossRefPubMedGoogle Scholar
  23. Chantada GL, Fandiño A, Raslawski EC et al (2005) Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. Pediatr Blood Cancer 44:455-460CrossRefPubMedGoogle Scholar
  24. Chantada GL, Casco F, Fandiño AC et al (2007) Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology 114:2083-2089CrossRefPubMedGoogle Scholar
  25. Chantada GL, Fandino AC, Carcaboso AM et al (2009) A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci 50:1492-1496CrossRefPubMedGoogle Scholar
  26. Chevez-Barrios P, Chintagumpala M, Mieler W et al (2005) Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by gancyclovir. J Clin Oncol 23:7927-7935CrossRefPubMedGoogle Scholar
  27. Donovan SL, Schweers B, Martins R, Johnson D, Dyer MA (2006) Compensation by tumor suppressor genes during retinal development in mice and humans. BMC Biol 4:14CrossRefPubMedGoogle Scholar
  28. Doz F, Khelfaoui F, Mosseri V et al (1994) The role of chemotherapy in orbital involvement of retinoblastoma. Cancer 74:722-732CrossRefPubMedGoogle Scholar
  29. Doz F, Neuenschwander S, Plantaz D et al (1995) Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Française d’Oncologie Pédiatrique. J Clin Oncol 13:902-909PubMedGoogle Scholar
  30. Dunkel I, Aledo A, Kernan N et al (2000) Successful treatment of metastatic retinoblastoma. Cancer 89:2117-2121CrossRefPubMedGoogle Scholar
  31. Dunkel IJ, Lee TC, Shi W et al (2007) A phase II trial of carboplatin for intraocular retinoblastoma. Pediatr Blood Cancer 49:643-648CrossRefPubMedGoogle Scholar
  32. Dyer MA, Rodriguez-Galindo C, Wilson MW (2005) Use of preclinical models to improve treatment of retinoblastoma. PLoS Med 2:e332CrossRefPubMedGoogle Scholar
  33. Elison JR, Cobrinik D, Claros N, Abramson DH, Lee TC (2006) Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol 124:1269-1275CrossRefPubMedGoogle Scholar
  34. Eng G, Li FP, Abramson DH et al (1993) Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85:1121-1128CrossRefPubMedGoogle Scholar
  35. Ericson LA, Rosengren BH (1961) Present therapeutic resources in retinoblastoma. Acta Ophthalmol 39:569-576Google Scholar
  36. Ericson LA, Kalberg B, Rosengren BH (1964) Trials of intravitreal injections of chemotherapeutic agents in rabbits. Acta Ophthalmol 42:721-726Google Scholar
  37. Fisher PG, Kadan-Lottick NS, Koroner DN (2002) Intrathecal thiotepa: reappraisal of an established therapy. J Pediatr Hematol Oncol 24:274-278CrossRefPubMedGoogle Scholar
  38. Frangoul H, Ames MM, Mosher RB et al (1999) Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: a report from the Children’s Cancer Group. Clin Cancer Res 5:3956-3962PubMedGoogle Scholar
  39. Gallie B, Budning A, DeBoer G et al (1996) Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 114:1321-1328CrossRefPubMedGoogle Scholar
  40. Ghate D, Edelhauser HF (2006) Ocular drug delivery. Expert Opin Drug Deliv 3:275-287CrossRefPubMedGoogle Scholar
  41. Ghate D, Brook W, McCarey BE, Edelhauser HF (2007) Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci 48:2230-2237CrossRefPubMedGoogle Scholar
  42. Gilbert JA, Simpson AE, Rudnick DE, Geroski DH, Aaberg TM, Edelhauser HF (2003) Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix. J Control Rel 20:409-417CrossRefGoogle Scholar
  43. Gombos D, Kelly A, Coen P, Kingston J, Hungerford J (2002) Retinoblastoma treated with primary chemotherapy alone: the significance of tumor size, location, and age. Br J Ophthalmol 86:80-83CrossRefPubMedGoogle Scholar
  44. Gombos DS, Hungerford J, Abramson DH et al (2007) Secondary acute myelogenous leukemia in patients with retinoblastoma. Ophthalmology 114:1378-1383CrossRefPubMedGoogle Scholar
  45. Gorodetsky R, Peylan-Ramu N, Reshef A, Gaberman E, Levdansky L, Marx G (2005) Interactions of carboplatin with fibrin(ogen), implications for local slow release chemotherapy. J Control Release 102:235-245CrossRefPubMedGoogle Scholar
  46. Gündüz K, Shields CL, Shields JA et al (1998) The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma. Arch Ophthalmol 116:1613-1617PubMedGoogle Scholar
  47. Gündüz K, Muftuoglu O, Gunalp I, Unal E, Tacyildiz N (2006) Metastatic retinoblastoma: clinical features, treatment, and prognosis. Ophthalmology 113:1558-1566CrossRefPubMedGoogle Scholar
  48. Harbour JW, Murray TG, Hamasaki D et al (1996) Local carboplatin therapy in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 37:1892-1898PubMedGoogle Scholar
  49. Hayden B, Murray T, Scott I et al (2000) Subconjunctival carboplatin in retinoblastoma. Impact of tumor burden and dose schedule. Arch Ophthalmol 118:1549-1554CrossRefPubMedGoogle Scholar
  50. Hayden BC, Jockovich M-E, Murray TG et al (2004) Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci 45:3644-3649CrossRefPubMedGoogle Scholar
  51. Heideman RL, Cole DE, Balis F et al (1989) Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49:736-741PubMedGoogle Scholar
  52. Honavar SG, Singh A, Shields CL et al (2002) Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 120:923-931PubMedGoogle Scholar
  53. Hungerford J, Toma N, Plowman P, Kingston J (1995) External beam radiotherapy for retinoblastoma: I Whole eye technique. Br J Ophthalmol 79:109-111CrossRefPubMedGoogle Scholar
  54. Inomata M, Kaneko A (1987) Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res 78:858-868PubMedGoogle Scholar
  55. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA (1992) Effects of a Rb mutation in the mouse. Nature 359:295-300CrossRefPubMedGoogle Scholar
  56. Jubran RF, Erdreich-Epstein A, Butturini A, Murphree AL, Villablanca JG (2004) Approaches to treatment for extraocular retinoblastoma. Children’s Hospital Los Angeles experience. J Pediatr Hematol Oncol 26:31-34CrossRefPubMedGoogle Scholar
  57. Kaneko A, Suzuki S (2003) Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol 33:601-607CrossRefPubMedGoogle Scholar
  58. Khelfaoui F, Validire P, Auperin A et al (1996) Histopathologic risk factors in retinoblastoma. A retrospective study of 172 patients treated in a single institution. Cancer 77:1206-1213CrossRefPubMedGoogle Scholar
  59. Kingston J, Hungerford J, Madreperla S, Plowman P (1996) Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 114:1339-1343CrossRefPubMedGoogle Scholar
  60. Kiratli H, Bilgiç S, Özerdem U (1998) Management of massive orbital involvement of intraocular retinoblastoma. Ophthalmology 105:322-326CrossRefPubMedGoogle Scholar
  61. Kremens B, Wieland R, Reinhard H et al (2003) High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 31:281-284CrossRefPubMedGoogle Scholar
  62. Krishnakumar S, Mallikarjuna K, Desai N et al (2004) Multidrug resistance proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol 88:1521-1526CrossRefPubMedGoogle Scholar
  63. Kupfer C (1953) Retinoblastoma treated with intravenous nitrogen mustard. Am J Ophthalmol 36:1721-1723PubMedGoogle Scholar
  64. Laurie NA, Gray JK, Zhang J et al (2005) Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 11:7569-7578CrossRefPubMedGoogle Scholar
  65. Laurie NA, Donovan SL, Shih C-S et al (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444:61-66CrossRefPubMedGoogle Scholar
  66. Lee EY, Chang CY, Hu N et al (1992) Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294CrossRefPubMedGoogle Scholar
  67. Lee TC, Hayashi NI, Dunkel IJ, Beaverson K, Novetsky D, Abramson DH (2003) New retinoblastoma tumor formation in children initially treated with systemic carboplatin. Ophthalmology 110:1989-1995CrossRefPubMedGoogle Scholar
  68. Li SL, Molokhia SA, Jeon EK (2004) Asessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm Res 21:2175-2184CrossRefPubMedGoogle Scholar
  69. Lonsdale D, Berry DH, Holcomb TM et al (1968) Chemotherapeutic trials in patients with metastatic retinoblastoma. Cancer Chemother Rep 52:631-634PubMedGoogle Scholar
  70. Majumdar S, Mitra AK (2006) Chemical modification and formulation approaches to elevated drug transport accross cell membranes. Expert Opin Drug Deliv 3:511-527CrossRefPubMedGoogle Scholar
  71. Mannermaa E, Vellonen K-S, Urtti A (2006) Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 58:1136-1163CrossRefPubMedGoogle Scholar
  72. Marsubara H, Makimoto A, Higa T et al (2005) A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 35:763-766CrossRefGoogle Scholar
  73. Mendelsohn M, Abramson DH, Madden T, Tong W, Tran H, Dunkel I (1998) Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol 116:1209-1212PubMedGoogle Scholar
  74. Menon BS, Juraida E, Alagaratnam J et al (2007) Chemoreduction for intraocular retinoblastolma in Malaysia. J Pediatr Hematol Oncol 29:2-4CrossRefPubMedGoogle Scholar
  75. Mohney B, Robertson D, Schomberg P, Hodge D (1998) Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J Ophthalmol 126:269-277CrossRefPubMedGoogle Scholar
  76. Mohri M (1993) The technique of selective ophthalmic arterial infusion for conservative treatment of recurrent intraocular retinoblastoma. Keio Igaku 70:679-687Google Scholar
  77. Mulvihill A, Budning A, Jay V et al (2003) Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 121:1120-1124CrossRefPubMedGoogle Scholar
  78. Murphree A, Villablanca J, Deegan W et al (1996) Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 114:1348-1356CrossRefPubMedGoogle Scholar
  79. Mustafa M, Jamshed A, Khafaga Y et al (1999) Adjuvant chemotherapy with vincristine, doxorubicin, and cyclophosphamide in the treatment of postenucleation high risk retinoblastoma. J Pediatr Hematol Oncol 21:364-369CrossRefPubMedGoogle Scholar
  80. Namouni F, Doz F, Tanguy M et al (1997) High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer 33:2368-2375CrossRefPubMedGoogle Scholar
  81. Nenadov Beck M, Balmer A, Dessing C, Pica A, Munier F (2000) First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 18:2881-2887Google Scholar
  82. Nishimura S, Sato T, Ueda H, Ueda K (2001) Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol 19:4182-4183PubMedGoogle Scholar
  83. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C (1998) Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315-318CrossRefPubMedGoogle Scholar
  84. Pardue MT, Hejny C, Gilbert JA, Phillips MJ, Geroski DH, Edelhauser HF (2004) Retinal function after subconjunctival injection of carboplatin in fibrin sealant. Retina 24:776-782CrossRefPubMedGoogle Scholar
  85. Pratt CB, Crom DB, Howarth C (1985) The use of chemotherapy for extraocular retinoblastoma. Med Pediatr Oncol 13:330-333CrossRefPubMedGoogle Scholar
  86. Pratt CB, Fontanesi J, Chenaille P et al (1994) Chemotherapy for extraocular retinoblastoma. Pediatr Hematol Oncol 11:301-309CrossRefPubMedGoogle Scholar
  87. Pui C-H, Ribeiro RC, Hanckok M (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682-1687CrossRefPubMedGoogle Scholar
  88. Ranta V-P, Urtti A (2006) Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev 58:1164-1181CrossRefPubMedGoogle Scholar
  89. Robinson MR, Lee SS, Kim H et al (2006) A rabbit model for assessing the ocular barriers to the trasscleral delivery of triamcinolone acetonide. Exp Eye Res 82:479-487CrossRefPubMedGoogle Scholar
  90. Rodriguez-Galindo C, Radomski KM, Stewart CF, Furman W, Santana VM, Houghton PJ (2000) Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol 35:385-402CrossRefPubMedGoogle Scholar
  91. Rodriguez-Galindo C, Wilson MW, Haik BG et al (2003a) Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 21:2019-2025CrossRefPubMedGoogle Scholar
  92. Rodriguez-Galindo C, Wilson MW, Haik BG et al (2003b) Treatment of metastatic retinoblastoma. Ophthalmology 110:1237-1240CrossRefPubMedGoogle Scholar
  93. Rodriguez-Galindo C, Chantada GL, Haik B, Wilson MW (2007) Retinoblastoma: current treatment and future perspectives. Curr Treat Options Neurol 9:294-307CrossRefPubMedGoogle Scholar
  94. Saarinen UM, Sariola H, Hovi L (1991) Recurrent disseminated retinoblastoma treated with high-dose chemotherapy, total body irradiation, and autologous bone marrow rescue. Am J Pediatr Hematol Oncol 13:315-319CrossRefPubMedGoogle Scholar
  95. Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG (2007) Macular retinoblastoma: Evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology 114:162-169CrossRefPubMedGoogle Scholar
  96. Schiavetti A, Hadjistilianou T, Clerico A, Bonci E, Ragni G, Castello MA (2005) Conservative therapy in intraocular retinoblastoma. response/recurrence rate. J Pediatr Hematol Oncol 27:3-6CrossRefPubMedGoogle Scholar
  97. Schmack I, Hubbard B, Kang SJ, Aaberg TM, Grossniklaus HE (2006) Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 142:310-315CrossRefPubMedGoogle Scholar
  98. Schouten-van Meeteren A, Moll A, Imhof S, Veerman A (2002) Chemotherapy for retinoblastoma: an expan­ding area of clinical research. Med Pediatr Oncol 38:428-438CrossRefPubMedGoogle Scholar
  99. Schueler AO, Anastassiou G, Jurklies C, Havers W, Wieland R, Bornfeld N (2006) De novo intraocular retinoblastoma development after chemotherapy in patients with hereditary retinoblastoma. Retina 26:425-431CrossRefPubMedGoogle Scholar
  100. Schvartzman E, Chantada G, Fandiño A, de Dávila MT, Raslawski E, Manzitti J (1996) Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol 14:1532-1536PubMedGoogle Scholar
  101. Scott I, Murray T, Feuer W et al (1999) External beam radiotherapy in retinoblatoma. Tumor control and comparison of 2 techniques. Arch Ophthalmol 117:766-770CrossRefPubMedGoogle Scholar
  102. Seregard S, Kock B, TRampe E (1995) Intravitreal chemotherapy for recurrent retinoblastoma in an only eye. Br J Ophthalmol 79:194-195CrossRefPubMedGoogle Scholar
  103. Shields CL, Shields JA (1999) Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 36:8-18PubMedGoogle Scholar
  104. Shields CL, Shields JA, Needle M et al (1997) Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 104:2101-2111PubMedGoogle Scholar
  105. Shields CL, Meadows AT, Shields JA, Carvalho C, Smith A (2001) Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 119:1269-1272CrossRefPubMedGoogle Scholar
  106. Shields CL, Honavar SG, Meadows AT et al (2002a) Chemoreduction plus focal therapy for retinoblastoma: Factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 133:657-664CrossRefPubMedGoogle Scholar
  107. Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ (2002b) Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 120:460-464CrossRefPubMedGoogle Scholar
  108. Shields CL, Shelil A, Cater J, Meadows AT, Shields JA (2003) Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol 121:1571-1576CrossRefPubMedGoogle Scholar
  109. Shields CL, Mashayekhi A, Cater J et al (2005) Macular retinoblastoma managed with chemoreduction: Analysis of tumor control with or without adjuvant thermotherapy in 68 tumors. Arch Ophthalmol 123:765-773CrossRefPubMedGoogle Scholar
  110. Simpson AE, Gilbert JA, Rudnick DE, Geroski DH, Aaberg TM, Edelhauser HF (2002) Transscleral diffusion of carboplatin. an in vitro and in vivo study. Arch Ophthalmol 120:1069-1074CrossRefPubMedGoogle Scholar
  111. Smith MA, Rubinstein L, Ungerleider RS (1994) Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 23:86-98CrossRefPubMedGoogle Scholar
  112. Toma N, Hungerford J, Plowman P, Kingston J, Doughty D (1995) External beam radiotherapy for retinoblastoma: II Lens sparing technique. Br J Ophthalmol 79:112-117CrossRefPubMedGoogle Scholar
  113. Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131-1135CrossRefPubMedGoogle Scholar
  114. Uusitalo M, Van Quill K, Scott I, Matthay KK, Murray T, O’Brien J (2001) Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 119:41-48CrossRefPubMedGoogle Scholar
  115. Van Quill KR, Dioguardi PK, Tong CT et al (2005) Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 112:1151-1158CrossRefPubMedGoogle Scholar
  116. Wilson MW, Haik BG, Liu T, Merchant TE, Rodriguez-Galindo C (2005) Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma. Am J Ophthalmol 140:397-406PubMedGoogle Scholar
  117. Wilson MW, Fraga CH, Fuller CE et al (2006) Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest Ophthalmol Vis Sci 47:1269-1273CrossRefPubMedGoogle Scholar
  118. Wilson MW, Haik BG, Billups CA, Rodriguez-Galindo C (2007) Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: is there a preventive effect? Ophthalmology 114:2077-2082CrossRefPubMedGoogle Scholar
  119. Zelter M, Damel A, Gonzalez G, Schwartz L (1991) A prospective study on the treatment of retinoblastoma in 72 patients. Cancer 68:1685-1690CrossRefPubMedGoogle Scholar
  120. Zhang J, Schweers B, Dyer MA (2004) The first knockout mouse model of retinoblastoma. Cell Cycle 3:952-959PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Dana-Farber Cancer Institute and Children’s Hospital Harvard Medical SchoolBostonUSA

Personalised recommendations